BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
377.63
-4.64 (-1.21%)
At close: Oct 23, 2026, 4:00 PM EDT
375.00
-2.63 (-0.70%)
Pre-market: Oct 26, 2026, 7:08 AM EDT
BeOne Medicines AG Employees
BeOne Medicines AG had 12,000 employees as of June 30, 2026. The number of employees increased by 1,000 or 9.09% compared to the same quarter last year.
Employees
12,000
Change (1Y)
1,000
Growth (1Y)
9.09%
Revenue / Employee
$510,747
Profits / Employee
$54,642
Market Cap
42.94B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 12,000 | 1,000 | 9.09% | 12,000 | 0 |
| Mar 31, 2026 | 12,000 | 1,000 | 9.09% | 12,000 | 0 |
| Dec 31, 2025 | 12,000 | 1,000 | 9.09% | 12,000 | 0 |
| Sep 30, 2025 | 11,000 | 1,000 | 10.00% | 11,000 | 0 |
| Jun 30, 2025 | 11,000 | 1,000 | 10.00% | 11,000 | 0 |
| Mar 31, 2025 | 11,000 | 1,000 | 10.00% | 11,000 | 0 |
| Dec 31, 2024 | 11,000 | 400 | 3.77% | 11,000 | 0 |
| Jun 30, 2024 | 10,000 | 600 | 6.38% | 10,000 | 0 |
| Mar 31, 2024 | 10,000 | 600 | 6.38% | 10,000 | 0 |
| Dec 31, 2023 | 10,600 | 1,600 | 17.78% | 10,600 | 0 |
| Mar 31, 2023 | 9,400 | 1,100 | 13.25% | 9,400 | 0 |
| Dec 31, 2022 | 9,000 | 1,000 | 12.50% | 9,000 | 0 |
| Sep 30, 2022 | 9,000 | 1,400 | 18.42% | 9,000 | 0 |
| Mar 31, 2022 | 8,300 | 2,900 | 53.70% | 8,300 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Regeneron Pharmaceuticals | 15,410 |
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 3,119 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| argenx SE | 1,863 |
| Insmed | 1,664 |
ONC News
- 15 hours ago - BeOne Medicines presents new data across solid tumor disease areas at ESMO 2026 - TheFly
- 2 days ago - BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026 - Business Wire
- 2 days ago - BeOne Medicines (ONC) Reports Promising Phase 3 Survival Data for HER2-Positive ... - GuruFocus
- 2 days ago - BeOne Medicines reports ‘sustained survival benefit’ with TEVIMBRA-ZIIHERA combo - TheFly
- 2 days ago - BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer - Business Wire
- 4 days ago - BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5 - Business Wire
- 7 days ago - BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026 - Business Wire
- 10 days ago - BeOne Medicines price target raised to $425 from $405 at Morgan Stanley - TheFly